Avalo Therapeutics AVTX Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's unrealized gains (losses) on available-for-sale securities?
- Avalo Therapeutics (AVTX) reported unrealized gains (losses) on available-for-sale securities of -$74K in Q1 2026.
- What does unrealized gains (losses) on available-for-sale securities mean?
- Represents the unrealized gains or losses on investment securities classified as available-for-sale, which are recorded in equity rather than the income statement. This metric captures the impact of market interest rate changes and credit quality shifts on the company's liquid investment portfolio. It provides insight into the performance of the company's treasury management and the potential liquidity available from its investment holdings.